Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allarity Therapeutics Inc

1.00
-0.0398-3.83%
Volume:143.99K
Turnover:145.67K
Market Cap:15.08M
PE:-0.18
High:1.04
Open:1.04
Low:1.00
Close:1.04
Loading ...

Company Profile

Company Name:
Allarity Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
7
Office Location:
24 School Street,2nd Floor,Boston,Massachusetts,United States
Zip Code:
02108
Fax:
- -
Introduction:
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Gerald W. McLaughlin
Chairman of the Board
Thomas H. Jensen
Chief Executive Officer and Director
Joan Brown
Director, Financial Reporting and Principal Accounting Officer
Laura E. Benjamin
Independent Director
Jesper Hoiland
Director

Shareholders

Name
Position
Thomas H. Jensen
Chief Executive Officer and Director
Jeffrey S. Ervin
Chief Financial Officer
Jeremy R. Graff
President and Chief Development Officer
Joan Brown
Director, Financial Reporting and Principal Accounting Officer
Steen Knudsen
Chief Scientific Officer